Huons Global’s flagship neuromodulator containing 200 units of 99.8% ultra-pure botulinum toxin Type A. Clinically validated for rapid onset (3-7 days) and extended duration (2-8 months). FDA-equivalent approved formulation with 0.5mg human serum albumin stabilizer for enhanced safety profile.

Therapeutic Advantages

Micro-Diffusion Technology

Clinical Specifications

Protocol Requirements

*MD-administered only. Contraindications include neuromuscular disorders and aminoglycoside use. Clinical outcomes may vary ±20% based on patient metabolism and injection technique. Report adverse events to local health authority.